Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma

The purpose of the present study was to evaluate the potency of the proteasome inhibitor bortezomib±gemcitabine in vitro and in vivo in pancreatic carcinoma. For in vivo testing, an orthotopic syngeneic mouse model which is very close to the biological situation has been used. In particular, the study focused on the impact of bortezomib on angiogenesis. It could be shown that bortezomib induced apoptosis and inhibited proliferation of pancreatic carcinoma very efficiently in vitro. In contrast, in an orthotopic pancreatic adenocarcinoma mouse model gemcitabine treatment inhibited tumor growth, while bortezomib p…